157 related articles for article (PubMed ID: 9543008)
41. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
Wierzbicki PM; Adrych K; Kartanowicz D; Dobrowolski S; Stanislawowski M; Chybicki J; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():63-70. PubMed ID: 20083853
[TBL] [Abstract][Full Text] [Related]
42. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
43. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.
Corbin S; Neilly ME; Espinosa R; Davis EM; McKeithan TW; Le Beau MM
Cancer Res; 2002 Jun; 62(12):3477-84. PubMed ID: 12067991
[TBL] [Abstract][Full Text] [Related]
44. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
45. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
46. [Association of fragile histidine triad gene (FHIT) with susceptibility to esophageal cancer. A preliminary study].
Li W; Wang X; Cheng G
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):258-60. PubMed ID: 10920977
[TBL] [Abstract][Full Text] [Related]
47. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
48. FHITness and cancer.
Druck T; Berk L; Huebner K
Oncol Res; 1998; 10(7):341-5. PubMed ID: 10063967
[TBL] [Abstract][Full Text] [Related]
49. [Sequence analyses of aberrant FHIT transcripts in gastric cancer cell lines].
Lee SH; Kim HS
Korean J Gastroenterol; 2003 Dec; 42(6):476-83. PubMed ID: 14695704
[TBL] [Abstract][Full Text] [Related]
50. FHIT alterations in breast cancer.
Ingvarsson S
Semin Cancer Biol; 2001 Oct; 11(5):361-6. PubMed ID: 11562178
[TBL] [Abstract][Full Text] [Related]
51. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
52. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding.
Trapasso F; Krakowiak A; Cesari R; Arkles J; Yendamuri S; Ishii H; Vecchione A; Kuroki T; Bieganowski P; Pace HC; Huebner K; Croce CM; Brenner C
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1592-7. PubMed ID: 12574506
[TBL] [Abstract][Full Text] [Related]
53. [Ectogenous fragile histidine triad gene inhibits the malignant phenotype of human lung cancer cell line A549 in vitro and in vivo].
Zhang LQ; Wang H; Lai BT; Yue WT; Zhan XP; Yang XH; Zhang CY; Zhang TM
Zhonghua Jie He He Hu Xi Za Zhi; 2005 May; 28(5):333-6. PubMed ID: 15949315
[TBL] [Abstract][Full Text] [Related]
54. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases.
Brenner C
Biochemistry; 2002 Jul; 41(29):9003-14. PubMed ID: 12119013
[TBL] [Abstract][Full Text] [Related]
55. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
56. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
[TBL] [Abstract][Full Text] [Related]
57. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
58. Chemical Proteomics of the Tumor Suppressor Fhit Covalently Bound to the Cofactor Ap
Herzog D; Jansen J; Mißun M; Diederichs K; Stengel F; Marx A
J Am Chem Soc; 2022 May; 144(19):8613-8623. PubMed ID: 35522782
[TBL] [Abstract][Full Text] [Related]
59. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
60. Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation.
Guo Z; Vishwanatha JK
Mol Cell Biochem; 2000 Jan; 204(1-2):83-8. PubMed ID: 10718628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
